In 2010, the Company expects to advance the clinical development of its pipeline products as follows: (i) to commence clinical trials in China for its enterovirus 71 (EV 71) vaccine and Japanese encephalitis vaccine upon receiving approval of its clinical trial applications from SFDA; (ii) to file the clinical trial application with the SFDA for its pneumococcal conjugate vaccine; and (iii) to commence clinical trials in China for the mumps vaccine under development at Sinovac Dalian upon receiving approval for its clinical trial application from the SFDA The Company intends to continue executing its business plan at the Sinovac Dalian and the Changping facilities to increase production capacity of its commercialized vaccines and prepare for the commercialization of its pipeline products.
Conference Call Details
The Company will host a conference call on Thursday, May 13, 2010 at 8:00
p.m. EDT (8:00 a.m. on May 14, 2010 China Standard Time) to review the
Company's financial results for the first quarter ended March 31, 2010 and
provide an update on recent corporate developments. To access the conference
call, please dial 1-877-407-4018 (USA) or 1-201-689-8471 (international). A
replay of the call will be available from 11:00 p.m. EDT on May 13, 2010 until
May 27, 2010. To access the replay, please dial 1-877-660-6853 (USA) or
1-201-612-7415 (international) and r
|SOURCE Sinovac Biotech Ltd.|
Copyright©2010 PR Newswire.
All rights reserved